Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its subsidiary, Merveille.ai, in the field of obesity treatment. Utilizing advanced artificial intelligence, Merveille.ai has identified a promising new therapeutic candidate, culminating in a strategic patent filing.

Capitalizing on Hoth Therapeutics' diverse portfolio, Merveille.ai employed a sophisticated large language model to analyze and identify synergies within existing compounds. This innovative approach has led to the discovery of a potential obesity therapeutic that complements Hoth's existing lineup.

In an ambitious move to propel this discovery towards clinical application, Merveille.ai is set to embark on a pre-clinical study in 2024. This study will integrate cutting-edge large language model technologies to optimize the research process, enhancing the precision and efficiency of the developmental pipeline.

Additionally, Merveille.ai has joined the prestigious Nvidia Developer Program. This collaboration underscores the subsidiary's commitment to leveraging top-tier computational resources and AI expertise to advance its research and development efforts in therapeutic discovery.

As Merveille.ai progresses to the pre-clinical study phase, the focus will be on validating the therapeutic's efficacy and safety.  This milestone reflects Hoth Therapeutics' and Merveille.ai's dedication to innovation and excellence in addressing complex health challenges like obesity.